Omics tools offer the opportunity to characterize and track traditional food and industrial fermentation. Bioinformatics, through machine learning, and other advanced statistical approaches, able to parse the fermentation process and predict the evolution and metabolic yields of food microbial ecosystems. By assembling a microbial-made consortival, the progress of biotechnology will also be able to increase the nutritional value and organoleptic characteristics of fermented food, preserve, at the same time, the potential of microbial consortiums autochthonous and metabolic pathways, which are difficult to reproduce. Preserving traditional methods contribute to protecting hidden values from local biodiversity, and exploiting their potential in industrial processes with the final objectives guaranteeing food security and safety, even in developing countries.
Biotechnology and therapeutic-based therapeutial strategies for age-related macular degeneration. Part I: Biomaterial-based drug delivery device
The age-related macular degeneration (AMD) is a chronic neurodegenerative eye disease that can be treated in the latest, and the main causes of blindness in more than 65 years. It is characterized by slow developments and the existence of many factors, highlights associated with diet, genetic inheritance and environmental conditions, present at each stage of the disease. The current therapeutic approach, mainly consists of administration of intraocular drugs, only used to eliminate symptoms and / or to exceed the development of the disease.
Furthermore, they are too simple and ignore the complexity of the disease and large differences in the symptomatology between patients. Due to the broad impact of AMD and the absence of current clinical solutions, the development of a biomaterial-based approach for subjective and controlled therapeutic and biomolecular delivery represents the main challenges for the defeat of neurodegenerative diseases.
Here we present a critical review of the AMD therapy approach that is available and in development, from biomaterials and biotechnology perspectives. We highlight the benefits and limitations and we estimate the upcoming alternatives based on new biomaterials and biotechnology methods. In the first part we expose the physiological and clinical aspects of the disease, focusing on several factors that gave the origin of interference and highlight the contribution of these factors to the trigger of every step of the disease. Then we analyze available and in the development of biomaterial-based drug delivery devices (DDD), taking into account the characteristics of anatomy and functional from a healthy and sick retinal tissue.
RCSB Protein Data Banks: Strong new tools to explore biological 3D macromolecular structures for basic and applied research and applied in fundamental biology, biomedical, biotechnology, bioengineering and energy science
Collaboratory Research for Bioinformatics Structural Protein Data Bank (RCSB GDP), US Data Center for Global GDP Archives and Founder Members of the World Worldwide Protein Data Partners, serving tens of thousands of data deposits in America and Oceania and making 3D macromolecular structure data available at no cost and without Limitations to millions of users of RCSB.org worldwide, including> 660,000 educators, students and community members who want to know using pdb101.rcsb.org.
PDB data deposits include structural biologists using macromolecular crystallography, nuclear magnetic resonance spectroscopy, 3D electron microscope and micro-electron diffraction. Consumer GDP data that accesses our web portals includes researchers, educators and students who study fundamental biology, biomedical, biotechnology, bioengineering and energy science. Over the past 2 years, the RCSB GDP web portal which focuses on research (RCSB.org) has experienced a complete redesign, allowing increased searches with full Boolean operator logic and easier access to integrated GDP data with> 40 external biodata resources. New features and resources are explained in detail using examples that show the structure of SARS-COV-2 protein which was recently released and host cell protein relevant to understanding and overcoming Global Pandemics Covid-19.
Holistic Approach Banking Cell NGNokan Swiss Fetus: Optimizing Safe and Sustainable Substrate for Regenerative Treatment and Biotechnology
The iterative safety, quality and optimization driven by the selection of therapeutic cell sources has formed the basic rock in the core development for primary fetal progenitor cell therapy (FPC) in Switzerland for three decades. Pragmatic adjustable fetus transplant program is designed as a direct workflow for network procurement, maximizing traceability, safety, consistency, and robustness of cultured progeni cellular materials. The standardization of intact cell bioprocess has provided adequate insight into adequate conjugation of modern biotechnology progress with the current legislative, ethical and regulatory framework.

Pioneer translational progress in regenerative skin and musculoskeletal treatment continuously shows the potential for FPC therapy. Extensive technical and clinical actions were collected by managing pediatric burns and geriatric ulcers in Switzerland. The simultaneous industrial transposition of Dermal FPC banks, after good manufacturing practice, shows the wide potential of their therapeutic value. Furthermore, in Extenso, the exponential revalorization of Swiss FPC technology can be achieved through an integrative update of the model framework. Consideration of longitudinal and transverse aspects of simultaneous fetal network differential processing allows a better understanding of potential power expansion – unlimited in multi-tiered main FPC banks.
10X Loading Buffer |
L0504-005 |
GenDepot |
5X1ml |
EUR 92.4 |
10X TAE Buffer |
T8048-101 |
GenDepot |
1L |
EUR 106.8 |
TBS Buffer, 10X |
T8057-100 |
GenDepot |
1L |
EUR 138 |
TBS Buffer, 10X |
T8057-105 |
GenDepot |
5x1L |
EUR 343.2 |
HEK293-TetR (Neo) |
SC005-Neo |
GenTarget |
2 x 106 cell/ml x 1ml |
EUR 1452 |
Description: tetracycline repressor in HEK293 stable cell line with Neomycin fusion marker |
hTERT (CMV, Neo) lentivirus |
LVP1130-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Premade lentivirus expressing human TERT gene under suCMV promoter, containing Neomycin marker. |
hTERT (EF1a, Neo) lentivirus |
LVP1131-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Premade lentivirus expressing human TERT gene under EF1a promoter, containing Neomycin marker. |
rtTA (Neo) , Lentiviral particles |
LVP400-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 484.8 |
Description: Pre-made lentiviral particles expressing reverse tetracycline Transcriptional Activator (rtTA) under enhanced EF1a promoter with Neomycin antibioic marker, provided in DMEM medium with 10% FBS. |
10X KRB-IBMX Buffer |
122937 |
Mediomics |
1 Vial |
EUR 92.4 |
Binding/Coating Buffer (10X) |
85R-124 |
Fitzgerald |
250 ml |
EUR 259.2 |
Description: ELISA buffer for optimal coating and binding of antibodies and antigens |
10X TAE buffer solution |
A00239 |
Bio Basic |
500ml |
EUR 67.63 |
|
10x TAE Buffer Solution |
BA01801 |
Bioatlas |
6x100ml |
EUR 116.4 |
Description: High purity buffer for various PCR applications. |
10x PBS Buffer Solution |
BA01802 |
Bioatlas |
6x100ml |
EUR 116.4 |
Description: High purity buffer for various PCR applications. |
10x TBE Buffer Solution |
BA01804 |
Bioatlas |
6x100ml |
EUR 116.4 |
Description: High purity buffer for various PCR applications. |
Alkaline Phosphate Buffer, 10x |
K2191050-6 |
Biochain |
50 ml |
EUR 164.4 |
Description: Can be used for various proteomics studies in both normal and pathological cases. It is an excellent control and suitable for educational purposes. This product is prepared from whole tissue homogenates and has undergone SDS-PAGE quality control analysis. The protein is stored in a buffer with protease inhibitor cocktail fo prevent degradation. |
10x Gel Loading Buffer |
TG4038 |
TopoGen |
1ml |
EUR 187.2 |
Blocking Buffer, 10X, 250ML |
X109-250ML |
Arbor Assays |
250ML |
EUR 430.8 |
Blocking Buffer, 10X, 25ML |
X109-25ML |
Arbor Assays |
25ML |
EUR 146.4 |
10x Cell Isolation Buffer |
78563 |
BPS Bioscience |
5 ml |
EUR 25 |
Description: This buffer is intended for use with mammalian cells during magnetic cell isolation or single cell processing. This buffer is optimized and formulated to reduce nonspecific binding and cell clumping |
10x PARP Assay Buffer |
80602 |
BPS Bioscience |
1 ml |
EUR 45 |
Description: The 10x PARP Assay Buffer is optimized for use with BPS_x000D_Bioscience's poly(ADP) ribose polymerase (PARP) assay kits. |
10x HAT Assay Buffer |
50095 |
BPS Bioscience |
20 ml |
EUR 40 |
Description: Buffer optimized for use with BPS Bioscience's histone acetyltransferase (HAT) assay kits. |
CMV-TetR (Neo) Lentiviral particles |
LVP017-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 484.8 |
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under CMV promoter, with Neomycin antibiotic marker. |
β-Lactamase (Neo) lentiviral particles |
LVP335-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 418.8 |
Description: pre-made lentiviral particles expressing β-Lactamase gene. A Neomycin marker was expressed under RSV promoter. Particles is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
EF1a-TetR (Neo) Lentiviral particles |
LVP459-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 484.8 |
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under enhanced EF1a promoter with Neomycin antibioic marker. |
10X Tris-Glycine Native Buffer (Transfer buffer) |
T8052-050 |
GenDepot |
500ml |
EUR 96 |
10X Tris-Glycine Native Buffer (Transfer buffer) |
T8052-100 |
GenDepot |
2X500ml |
EUR 124.8 |
10X Tris-Glycine Native Buffer (Transfer buffer) |
T8052-101 |
GenDepot |
1L |
EUR 114 |
10X Tris-Glycine Native Buffer (Transfer buffer) |
T8052-200 |
GenDepot |
4X500ml |
EUR 153.6 |
10X Tris-Glycine Native Buffer (Transfer buffer) |
T8052-201 |
GenDepot |
2X1L |
EUR 153.6 |
10X Tris-Glycine Native Buffer (Transfer buffer) |
T8052-401 |
GenDepot |
4X1L |
EUR 198 |
LoxP GFP/RFP ColorSwitch (Neo) lentivirus |
LVP460-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 852 |
Description: Pre-made lentiviral particles expressing "LoxP-GFP-stop-LoxP-RFP-Stop" cassette under suCMV promoter. It also contains a Neomycin antibiotic selection marker under Rsv promoter. Virus is provided in DMEM medium with 10% FBS and 60ug/ml of polybrene. |
amfiEco Taq Reaction Buffer(2X) |
P0703-001 |
GenDepot |
1ml |
EUR 100.8 |
amfiEco Taq Reaction Buffer(2X) |
P0703-005 |
GenDepot |
5ml |
EUR 213.6 |
Aniline, 10X in acetate buffer |
91057 |
Biotium |
10ML |
EUR 133.2 |
Description: Minimum order quantity: 1 unit of 10ML |
10x PCR Buffer without MgCl2 |
ABP-PP-ERBF001 |
Allele Biotech |
1x1ml |
Ask for price |
|
10x PCR Buffer without MgCl2 |
ABP-PP-ERBF002 |
Allele Biotech |
2x1ml |
Ask for price |
|
10x PCR Buffer without MgCl2 |
ABP-PP-ERBF005 |
Allele Biotech |
5x1ml |
Ask for price |
|
10x PCR Buffer with MgCl2 |
ABP-PP-ERBFM01 |
Allele Biotech |
1x1ml |
Ask for price |
|
10x PCR Buffer with MgCl2 |
ABP-PP-ERBFM02 |
Allele Biotech |
2x1ml |
Ask for price |
|
10x PCR Buffer with MgCl2 |
ABP-PP-ERBFM05 |
Allele Biotech |
5x1ml |
Ask for price |
|
10x Tris-Glycine Buffer Solution |
BA01806 |
Bioatlas |
6x100ml |
EUR 116.4 |
Description: High purity buffer for various PCR applications. |
Dilution buffer R (10x); ELISPOT |
CT348 |
U-CyTech |
10 ml |
EUR 93.6 |
Dilution buffer T (10x); ELISPOT |
CT358 |
U-CyTech |
8 ml |
EUR 93.6 |
SuperBlot Western Transfer buffer 10X |
DG-WEST |
Bio Basic |
500ml |
EUR 136.56 |
|
Annexin V Binding Buffer (10x) |
EXB0019 |
ExBio |
N/A |
EUR 103.2 |
10X PBS Buffer , pH 7.4 |
P2100-050 |
GenDepot |
500ml |
EUR 105.6 |
10X PBS Buffer , pH 7.4 |
P2100-100 |
GenDepot |
1L |
EUR 109.2 |
Xpert Native Transfer Buffer(10X) |
P9001-050 |
GenDepot |
500ml |
EUR 111.6 |
Xpert Native Transfer Buffer(10X) |
P9001-100 |
GenDepot |
1L |
EUR 165.6 |
10X Tris-Glycine SDS buffer |
T8053-050 |
GenDepot |
500ml |
EUR 102 |
10X Tris-Glycine SDS buffer |
T8053-100 |
GenDepot |
2X500ml |
EUR 133.2 |
10X Tris-Glycine SDS buffer |
T8053-101 |
GenDepot |
1L |
EUR 118.8 |
10X Tris-Glycine SDS buffer |
T8053-104 |
GenDepot |
4 L |
EUR 183.6 |
10X Tris-Glycine SDS buffer |
T8053-200 |
GenDepot |
4X500ml |
EUR 163.2 |
10X Tris-Glycine SDS buffer |
T8053-201 |
GenDepot |
2X1L |
EUR 162 |
10X Tris-Glycine SDS buffer |
T8053-401 |
GenDepot |
4X1L |
EUR 206.4 |
TBS Buffer, 10X , Refill Pack |
T8057-401 |
GenDepot |
1 Gal |
EUR 218.4 |
Topo I Assay Buffer 10x |
TG4010 |
TopoGen |
1ml |
EUR 174 |
PBST buffer 10x Strength Solution |
PW004 |
Bio Basic |
500ml |
EUR 80.88 |
|
TBST buffer 10x Strength Solution |
PW009 |
Bio Basic |
500ml |
EUR 78.79 |
|
West-Ezier Washing Buffer(10X) |
W3873-050 |
GenDepot |
500ml |
EUR 141.6 |
10X Annexin V Binding Buffer |
1006-100 |
Biovision |
each |
EUR 235.2 |
10X Citrate Buffer *pH 6.0* |
10000 |
AAT Bioquest |
100 mL |
EUR 97 |
pWZL-Neo Retroviral Vector |
RTV-001-NEO |
Cell Biolabs |
10 ?g |
EUR 679.2 |
Description: Use this construct to clone your gene for downstream recombinant retroviral packaging |
SV40 large T-antigen (Neo), CMV lentiviral particles |
LVP016-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under suCMV promoter, containing Neomycin marker. |
SV40 large T-antigen (Neo), EF1a lentiviral particles |
LVP557-Neo |
GenTarget |
1x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Pre-made lentiviral particles expressing SV40 large T-antigen under EF1a promoter, containing Neomycin marker. |
CMV Control lentiviral particles (Neo) |
CMV-Null-Neo |
GenTarget |
1 x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Negative control lentivirus contains a null spacer insert under CMV promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter. |
EF1a Control lentiviral particles (Neo) |
EF1a-Null-Neo |
GenTarget |
1 x107 IFU/ml x 200ul |
EUR 418.8 |
Description: Negative control lentivirus contains a null spacer insert under EF1a promoter, serves as the negative control of lentivurs treatment for the specificity of any target expression effects. It also has the Neomycin marker under RSV promoter. |
amfiXpand Taq DNA Ploymerase Buffer*(2X) |
P0332-001 |
GenDepot |
1ml |
EUR 121.2 |
Taq DNA Polymerase (Mg2+ plus Buffer) |
P101-01 |
Vazyme |
1000 U |
EUR 145.2 |
Taq DNA Polymerase (Mg2+ plus Buffer) |
P101-02 |
Vazyme |
5000 U |
EUR 231.6 |
Taq DNA Polymerase (Mg2+ plus Buffer) |
P101-03 |
Vazyme |
10000 U |
EUR 314.4 |
Taq DNA Polymerase (Mg2+ free Buffer) |
P102-01 |
Vazyme |
1000 U |
EUR 145.2 |
Taq DNA Polymerase (Mg2+ free Buffer) |
P102-02 |
Vazyme |
5000 U |
EUR 231.6 |
Taq DNA Polymerase (Mg2+ free Buffer) |
P102-03 |
Vazyme |
10000 U |
EUR 314.4 |
PCR Buffer I, Mg Free 10X, Ammonium Rxn Buffer |
42-300 |
Genesee Scientific |
3 x 1.5ml/Unit |
EUR 285 |
1 L TBE BUFFER, 10X, LIQUID |
46-011-CM |
CORNING |
1L/pk |
EUR 141.6 |
Description: Media Catalog; Classical Media |
10X ELISA Wash Buffer (125 mL) |
0801060 |
Zeptometrix |
125 mL |
EUR 78.72 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
TG Buffer (TRIS-GLYCINE) 10X Solution |
A0028 |
Bio Basic |
4L |
EUR 113.76 |
|
10x Tris-Glycine-SDS Buffer Solution |
BA01807 |
Bioatlas |
6x100ml |
EUR 123.6 |
Description: High purity buffer for various PCR applications. |
Dilution buffer B (10x); ELISPOT (PVDF) |
CT364 |
U-CyTech |
8 ml |
EUR 93.6 |
Finegel SDS-PAGE Running Buffer(10X) |
F1504-050 |
GenDepot |
500ml |
EUR 181.2 |
Finegel SDS-PAGE Running Buffer(10X) |
F1504-100 |
GenDepot |
2x500ml |
EUR 241.2 |
TG Buffer (Tris-Glycine) 10X Solution |
UA0028 |
Bio Basic |
500ml |
EUR 71.28 |
|
10X ELISA Wash Buffer (125 mL) |
801060 |
Zeptometrix |
125 mL |
EUR 18 |
10X Red Blood Cell Lysis Buffer |
5831-100 |
Biovision |
each |
EUR 144 |
hTERT (CMV, Neo) lentivirus in PBS |
LVP1130-Neo-PBS |
GenTarget |
1x108 IFU/ml x 200ul |
EUR 852 |
Description: Concentrated lentivirus in PBS, expressing human TERT gene under suCMV promoter, containing Neomycin marker. |
hTERT (EF1a, Neo) lentivirus in PBS |
LVP1131-Neo-PBS |
GenTarget |
1x108 IFU/ml x 200ul |
EUR 852 |
Description: Concentrated lentivirus in PBS, expressing human TERT gene under EF1a promoter, containing Neomycin marker. |
rtTA (Neo) in PBS, Lentiviral particles |
LVP400-Neo-PBS |
GenTarget |
5x107 IFU/ml x 200ul |
EUR 608.4 |
Description: Pre-made lentiviral particles expressing reverse tetracycline Transcriptional Activator (rtTA) under enhanced EF1a promoter with Neomycin antibioic marker, concentrated particles provided in PBS solution. |
Color Switch, CRE report cell line: HEK293-loxP-GFP-RFP Neo) |
SC018-Neo |
GenTarget |
2x10E6 cell/ml x1ml |
EUR 5280 |
Description: CRE reporter cell line (Neo): HEK293 cell line expressing "LoxP-GFP-stop-LoxP-RFP" cassette with Neomycin antibiotic marker |
PCR Buffer I, 1.5mM Mg Final 10X Ammonium Rxn Buffer |
42-300M |
Genesee Scientific |
3 x 1.5ml/Unit |
EUR 285 |
CMV-TetR (Neo) Lentiviral particles in PBS |
LVP017-Neo-PBS |
GenTarget |
5x107 IFU/ml x 200ul |
EUR 608.4 |
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under CMV promoter, with Neomycin antibiotic marker. Particles pellet was re-suspended in PBS solution. |
EF1a-TetR (Neo) Lentiviral particles in PBS |
LVP459-Neo-PBS |
GenTarget |
5x107 IFU/ml x 200ul |
EUR 608.4 |
Description: Pre-made lentiviral particles expressing tetracycline regulator protein (TetR) under enhanced EF1a promoter with Neomycin antibioic marker. Particles was pellet down and re-suspended in PBS solution. |
LoxP GFP/RFP ColorSwitch (Neo) lentivirus (concentrated) |
LVP460-Neo-PBS |
GenTarget |
5x107 IFU/ml x 200ul |
EUR 1034.4 |
Description: Pre-made lentiviral particles expressing "LoxP-GFP-stop-LoxP-RFP-Stop" cassette under suCMV promoter. It also contains a Neomycin antibiotic selection marker under Rsv promoter. Virus was provied in PBS solution. |
HotStart Taq DNA Polymerase (Mg2+ Plus Buffer) |
RK20601 |
Abclonal |
25 U |
Ask for price |
|
TBE buffer (Tris-Borate-EDTA), 10x Solution |
A0026 |
Bio Basic |
4L |
EUR 112.72 |
|
TBS buffer (Tris-Buffered Saline), 10x Solution |
A0027 |
Bio Basic |
4L |
EUR 112.72 |
|
10X PBS Buffer , pH 7.4, Refill Pack |
P2100-204 |
GenDepot |
3.5L |
EUR 165.6 |
10X PBS Buffer , pH 7.4, Refill Pack |
P2100-208 |
GenDepot |
8L |
EUR 262.8 |
Xpert SDS-PAGE Gel Running Buffer(10X) |
P9000-050 |
GenDepot |
500ml |
EUR 116.4 |
Xpert SDS-PAGE Gel Running Buffer(10X) |
P9000-100 |
GenDepot |
1L |
EUR 165.6 |
Xpert Native Transfer Buffer(10X), Refill Pack |
P9001-204 |
GenDepot |
3.5 L |
EUR 262.8 |
TBS buffer (Tris-Buffered Saline), 10x Solution |
UA00279 |
Bio Basic |
500ml |
EUR 70.18 |
|
TE Buffer (Tris-EDTA), 10X, pH 7.4 |
USD8211 |
Bio Basic |
500ml |
EUR 77.23 |
|
Taq DNA Polymerase (Mg2+ plus Buffer, with dNTP) |
P101-d1 |
Vazyme |
1000 U |
EUR 163.2 |
Taq DNA Polymerase (Mg2+ plus Buffer, with dNTP) |
P101-d2 |
Vazyme |
5000 U |
EUR 320.4 |
Taq DNA Polymerase (Mg2+ plus Buffer, with dNTP) |
P101-d3 |
Vazyme |
10000 U |
EUR 490.8 |
Taq DNA Polymerase (Mg2+ free Buffer, with dNTP) |
P102-d1 |
Vazyme |
1000 U |
EUR 163.2 |
Taq DNA Polymerase (Mg2+ free Buffer, with dNTP) |
P102-d2 |
Vazyme |
5000 U |
EUR 320.4 |
Taq DNA Polymerase (Mg2+ free Buffer, with dNTP) |
P102-d3 |
Vazyme |
10000 U |
EUR 490.8 |
Western blot recycling stripping buffer, 50 ml (10X) |
90101 |
Alpha Diagnostics |
50 ml |
EUR 285.6 |
ELISA Plate Blocking Buffer concentrate (10X) BSA-based |
80060 |
Alpha Diagnostics |
50 ml |
EUR 242.4 |
TG-SDS Buffer (Tris-Glycine-SDS) 10X Solution |
A0030 |
Bio Basic |
4L |
EUR 113.76 |
|
3-D Life 10x CB-Buffer (pH 5.5) |
B10-3 |
Cellendes |
600 µl |
EUR 52.8 |
3-D Life 10x CB Buffer (pH 7.2) |
B20-3 |
Cellendes |
600 µL |
EUR 52.8 |
Citrate Buffer(10X), pH 6.0 for Antigen Retriever |
C7915-010 |
GenDepot |
100ml |
EUR 134.4 |
Citrate Buffer(10X), pH 6.0 for Antigen Retriever |
C7915-050 |
GenDepot |
500ml |
EUR 238.8 |
Some fetal tissues (eg, skin, cartilage, tendons, muscles, bones, lungs) can be harvested simultaneously and processed for obedient cell culture, set a unique model for sustainable therapeutic cellular supply chains. Here, we integrate fundamental, preclinical, clinical, and industrial developments to realize scientific progress supported by the Swiss FPC Banking and we focus on progress made for the date of FPC which can be derived from a single organ donation. The new single model of bioprocessing donation is proposed, achieving sustainable standards and potential production of billions of therapeutic doses that are affordable and efficient.